Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LENZ Therapeutics, Inc. (LENZ : NSDQ)

• Company Description    Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Lenz Therapeutics Inc., formerly known as Graphite Bio Inc., is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $5.96 Daily Weekly Monthly 20 Day Moving Average: 705,368 shares Shares Outstanding: 31.42 (millions) Market Capitalization: $187.26 (millions) Beta: 0.66 52 Week High: $50.40 52 Week Low: $4.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.19% 11.69% 12 Week -10.11% -12.02% Year To Date -62.75% -66.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 Lomas Santa Fe Dr. Suite 300 - Solana Beach,CA 92075 USA ph: 858-925-7000 fax: - ir@lenz-tx.com https://lenz-tx.com

• General Corporate Information    Officers Evert Schimmelpennink - Chief Executive Officer; President and Director Daniel Chevallard - Chief Financial Officer Jeff George - Director Frederic Guerard - Director James McCollum - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52635N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 31.42 Most Recent Split Date: 3.00 (0.14:1) Beta: 0.66 Market Capitalization: $187.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.01 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 30.47% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.85 Price/Cash Flow: - Price / Sales: 8.72 EPS Growth vs. Year Ago Period: -92.45% vs. Previous Quarter: 22.73% Sales Growth vs. Year Ago Period: 9.72% vs. Previous Quarter: 188.58% ROE 06/30/26 - -53.39 03/31/26 - -46.82 12/31/25 - -37.47 ROA 06/30/26 - -49.14 03/31/26 - -43.32 12/31/25 - -35.13 Current Ratio 06/30/26 - 13.55 03/31/26 - 10.40 12/31/25 - 14.23 Quick Ratio 06/30/26 - 13.31 03/31/26 - 10.26 12/31/25 - 14.09 Operating Margin 06/30/26 - -586.74 03/31/26 - -519.30 12/31/25 - - Net Margin 06/30/26 - -586.74 03/31/26 - -519.30 12/31/25 - - Pre-Tax Margin 06/30/26 - -586.72 03/31/26 - -516.91 12/31/25 - -427.62 Book Value 06/30/26 - 6.99 03/31/26 - 7.86 12/31/25 - 9.09 Inventory Turnover 06/30/26 - 0.62 03/31/26 - 0.81 12/31/25 - 0.43 Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©